Clinigence Holdings, Inc. (‘Clinigence’ or the ‘Company’) is providing an update to its shareholders. As previously announced on June 3, 2020, Clinigence sold certain of its intellectual property assets and patents, as well as liabilities of approximately $3.2 million, to Accountable Healthcare America, Inc. (‘AHA’) for an aggregate purchase price of $15 million of Preferred Stock of AHA. To further enhance shareholder value, the Board of Directors of Clinigence Holdings is announcing an operating restructuring plan and is also exploring strategic alternatives for their fully-reporting operating public entity, including the potential sale or merger of the Company. As part of this restructuring plan, Jacob ‘Kobi’ Margolin has announced his resignation as Chief Executive Officer of the Company. He will continue to serve as a director on the Board of the Company. Lawrence Schimmel, M.D., Co-Founder of the Company and current Chief Medical Officer, has been named Interim Chief Executive Officer of Clinigence Holdings.